BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38268032)

  • 21. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A feedback loop between lncRNA MALAT1 and DNMT1 promotes triple-negative breast cancer stemness and tumorigenesis.
    Hu Y; He Y; Luo N; Li X; Guo L; Zhang K
    Cancer Biol Ther; 2023 Dec; 24(1):2235768. PubMed ID: 37548553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HePTP promotes migration and invasion in triple-negative breast cancer cells via activation of Wnt/β-catenin signaling.
    Yu L; Wang C; Pan F; Liu Y; Ren X; Zeng H; Shi Y
    Biomed Pharmacother; 2019 Oct; 118():109361. PubMed ID: 31545274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CHD4-mediated loss of E-cadherin determines metastatic ability in triple-negative breast cancer cells.
    Luo CW; Wu CC; Chang SJ; Chang TM; Chen TY; Chai CY; Chang CL; Hou MF; Pan MR
    Exp Cell Res; 2018 Feb; 363(1):65-72. PubMed ID: 29305962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long non-coding RNA DGCR5 incudes tumorigenesis of triple-negative breast cancer by affecting Wnt/β-catenin signaling pathway.
    Jiang D; Wang C; He J
    J BUON; 2020; 25(2):702-708. PubMed ID: 32521856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MiR-6838-5p suppresses cell metastasis and the EMT process in triple-negative breast cancer by targeting WNT3A to inhibit the Wnt pathway.
    Liu G; Wang P; Zhang H
    J Gene Med; 2019 Dec; 21(12):e3129. PubMed ID: 31693779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer.
    Ryu WJ; Lee JD; Park JC; Cha PH; Cho YH; Kim JY; Sohn JH; Paik S; Choi KY
    Exp Mol Med; 2020 May; 52(5):832-842. PubMed ID: 32457491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-137 Suppresses Triple-Negative Breast Cancer Stemness and Tumorigenesis by Perturbing BCL11A-DNMT1 Interaction.
    Chen F; Luo N; Hu Y; Li X; Zhang K
    Cell Physiol Biochem; 2018; 47(5):2147-2158. PubMed ID: 29975921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coordinated regulation of WNT/β-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits.
    Giacomelli C; Jung J; Wachter A; Ibing S; Will R; Uhlmann S; Mannsperger H; Sahin Ö; Yarden Y; Beißbarth T; Korf U; Körner C; Wiemann S
    BMC Cancer; 2021 Dec; 21(1):1296. PubMed ID: 34863149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MiR-296-3p inhibits cell proliferation by the SOX4-Wnt/βcatenin pathway in triple-negative breast cancer.
    Tian D; Luo L; Wang T; Qiao J
    J Biosci; 2021; 46():. PubMed ID: 34785625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathologic characteristics of FBXW7-mutated colorectal adenocarcinoma and association with aberrant beta-catenin localization.
    Escobar D; Bushara O; Sun L; Liao J; Yang GY
    Hum Pathol; 2022 Jan; 119():51-58. PubMed ID: 34717891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Saikosaponin D from Radix Bupleuri suppresses triple-negative breast cancer cell growth by targeting β-catenin signaling.
    Wang J; Qi H; Zhang X; Si W; Xu F; Hou T; Zhou H; Wang A; Li G; Liu Y; Fang Y; Piao HL; Liang X
    Biomed Pharmacother; 2018 Dec; 108():724-733. PubMed ID: 30248540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversal of epithelial-mesenchymal transition and inhibition of tumor stemness of breast cancer cells through advanced combined chemotherapy.
    Cui Y; Zhao M; Yang Y; Xu R; Tong L; Liang J; Zhang X; Sun Y; Fan Y
    Acta Biomater; 2022 Oct; 152():380-392. PubMed ID: 36028199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miR-221/222 activate the Wnt/β-catenin signaling to promote triple-negative breast cancer.
    Liu S; Wang Z; Liu Z; Shi S; Zhang Z; Zhang J; Lin H
    J Mol Cell Biol; 2018 Aug; 10(4):302-315. PubMed ID: 30053090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tweaking EMT and MDR dynamics to constrain triple-negative breast cancer invasiveness by EGFR and Wnt/β-catenin signaling regulation.
    Shome R; Ghosh SS
    Cell Oncol (Dordr); 2021 Apr; 44(2):405-422. PubMed ID: 33398673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FSTL1 enhances chemoresistance and maintains stemness in breast cancer cells via integrin β3/Wnt signaling under miR-137 regulation.
    Cheng S; Huang Y; Lou C; He Y; Zhang Y; Zhang Q
    Cancer Biol Ther; 2019; 20(3):328-337. PubMed ID: 30336071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aberrant methylation of WD-repeat protein 41 contributes to tumour progression in triple-negative breast cancer.
    Wang H; Wu D; Cai L; Li X; Zhang Z; Chen S
    J Cell Mol Med; 2020 Jun; 24(12):6869-6882. PubMed ID: 32394588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states.
    Sulaiman A; McGarry S; Li L; Jia D; Ooi S; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Gadde S; Li X; Wang L
    Mol Oncol; 2018 Apr; 12(4):423-440. PubMed ID: 29316250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BCL11A enhances stemness and promotes progression by activating Wnt/β-catenin signaling in breast cancer.
    Zhu L; Pan R; Zhou D; Ye G; Tan W
    Cancer Manag Res; 2019; 11():2997-3007. PubMed ID: 31114347
    [No Abstract]   [Full Text] [Related]  

  • 40. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
    Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
    Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.